StockNow
Calendar
Log in
U.S. Markets

Alkermes’ (ALKS) orexin agonist shows potential to treat ADHD in early-stage trial, STAT News reports

StockNow breaking-news AI analysis

STAT News reported that an early-stage clinical trial of Alkermes' orexin agonist showed potential in treating ADHD.

1 stocks
ALKSAlkermes Inc. plc$43.65Current price

What do investors think?

Curious what other investors think?Log in to see reactions and join the conversation.
Log in to view reactions

StockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.

Today's market highlights

A selection of stories drawing attention in the market.

See more
Geopolitics

UKMTO has received a report of an incident involving a vessel transiting the Strait of Hormuz, reported at 07:30 UTC; tanker conducting an inbound transit was struck by an unknown projectile

Geopolitics

Yemeni Houthi official warns Egypt, Turkey and Pakistan will likely be targeted in the next stages

Geopolitics

US President Trump posts "Russia has unfortunately lost control of its Diesel Oil Industry due to its War with Ukraine"